Lower Urinary Tract Symptoms (LUTS) Clinical Trial
Official title:
Safety and Effectiveness Study of the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH
Evaluate the safety and effectiveness of the Zenflow Spring System in relieving LUTS associated with BPH.
Prospective, multi-center, multinational, 2:1 randomized, single-blinded, controlled clinical trial of the Zenflow Spring System. Patients randomized to the treatment group will undergo Zenflow Spring placement. Patients randomized to the control group will undergo a Sham procedure. Patients and site personnel administering follow-up assessments will be blinded to the randomized treatment through completion of the 3-month follow-up visit. Once a patient has completed their 3-month follow-up assessments, they will be unblinded. Following unblinding, patients who received a Sham procedure may elect to receive treatment with the Zenflow Spring System or alternatively they may exit the study. The duration of study participation is 60 months for patients who receive a Spring Implant and 3 months for subjects in the Control Arm. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03856242 -
Benign Prostatic Hyperplasia and Ischemic Heart DIsease
|
Phase 4 | |
| Recruiting |
NCT02592473 -
Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia
|
N/A | |
| Completed |
NCT01639794 -
Vesitirim™ in Men Postmarketing Observational Study
|
N/A | |
| Terminated |
NCT00743184 -
Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)
|
Phase 2 | |
| Completed |
NCT00947882 -
A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)
|
Phase 2 | |
| Recruiting |
NCT05341661 -
Butterfly Pivotal Study
|
N/A | |
| Completed |
NCT01846793 -
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
|
Phase 3 |